Exact Sciences Corporation

EXASintermediary

Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology. Its Cologuard test has become the leading non-invasive colorectal cancer screening tool, and its multi-cancer early detection test aims to transform cancer diagnosis.

⇄ Compare

Продукты и выручка

Доля выручки продукта

Структура выручки ($2.8B)

Статические данные (загрузка финансов…)

Screening (Cologuard) (55%)

Precision Oncology (Oncotype DX) (35%)

Other / Pipeline (10%)

Структура сегментов и ключевые клиенты

Подробности продукта

Cologuard (Colorectal Cancer)45%

Non-invasive stool DNA test for colorectal cancer screening

Oncotype DX (Breast Cancer)30%

Genomic test predicting breast cancer recurrence risk

Multi-Cancer Early Detection (MCED)10%

Blood-based test detecting multiple cancer types from a single draw

Связи цепочки поставок

Партнёры

Pfizer Inc.

Cancer screening combined with pharma treatment

Влияние: Low — co-marketing exploration

Eli Lilly and Company

Companion diagnostics for oncology drugs

Влияние: Low — diagnostic partnerships

Regeneron Pharmaceuticals

Genomic profiling for antibody therapies

Влияние: Low

Макро- и рыночный контекст

제약 / 바이오Новости сектора

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Предстоящие катализаторы

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI-анализ

Нажмите "Получить AI-анализ" для анализа цепочки поставок Exact Sciences Corporation.

Информация о компании

Штаб-квартира

Madison, Wisconsin, USA

Основана

1995

Сотрудники

7,200+

Веб-сайт

exactsciences.com

Обзор сектора — 제약 / 바이오

Новости сектора